Lupin
LUPINNSE

Lupin

₹2,293.3020.00 (0.88%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
F&O

Performance

Today’s low
2,269.50
Today’s high
2,297.10
52 week low
1,836.80
52 week high
2,494.00
Open price
2,282.00
Previous close
2,273.30
Live volume
6,13,853
Lower circuit
2,064.00
Upper circuit
2,522.60

Fundamentals

Market Cap
₹1,04,830Cr
ROE
23.76%
P/E Ratio(TTM)
19.57
EPS(TTM)
117.13
P/B Ratio
4.67
Dividend Yield
0.79%
Industry P/E
33.88
Book Value
490.96
Debt to Equity
0.29
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹7,615
+4.57%
Profit (Cr)
₹1,469
+24.41%
02k4k6k8k
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+33%
3Y CAGR+11%
Profit growthValue
1Y (TTM)+88%
3Y CAGR+61%

About

Founded by Dr. Desh Bandhu Gupta in 1968, Lupin's culture is driven by the vision of making quality healthcare accessible for all people. The company's central purpose, which it considers its 'North Star', is to catalyze treatments that transform hope into healing for patients everywhere. This purpose is anchored in three core commitments: providing relief from disease, innovating to unlock access at scale, and developing solutions for underserved communities. As a global pharmaceutical leader, Lupin has a strong presence across North America, EMEA, LATAM, APAC, and India, with its products distributed in over 100 markets. Its portfolio includes a wide range of generics, complex generics, specialty medicines, and biosimilars to expand access to quality healthcare for people globally. In its home market, the India business contributed 34% to total revenues in fiscal year 2025, ranking eighth in the Indian Pharmaceutical Market.;
CEO/MD
Vinita Gupta
Founded in
1968
NSE symbol
LUPIN

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
46.86%
Foreign Institutions
21.71%
Mutual Funds
16.93%
Other Domestic Institutions
8.39%
Retail And Others
6.12%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹1,807.70
+13.50 (0.75%)
L
    H
    4,33,619.8137.675.19
    ₹4,571.20
    -1.00 (0.02%)
    L
      H
      1,54,837.1072.4118.46
      CiplaCIPLA
      ₹1,389.40
      +6.10 (0.44%)
      L
        H
        1,12,193.5629.053.26
        ₹1,275.40
        -0.60 (0.05%)
        L
          H
          1,06,328.4925.582.81
          Livesquawk
          Lupin & Natco secure FDA approval for Eribulin Mesylate Injection for cancer treatment. The drug targets metastatic breast cancer, liposarcoma; expected U.S. sales of $43.7M/year.
          Livesquawk
          Lupin's CFO Swaminathan highlights focus on larger specialty drug deals. The company aims to maintain discipline on debt levels and risk management.
          2026
          7
          May
          Quarterly & Annual Result
          Release date
          12
          Feb
          Quarterly Result
          Release date
          2025
          6
          Nov
          Quarterly Result
          Release date
          5
          Aug
          Quarterly Result
          Release date

          25
          Jul
          Dividend
          Ex date
          ₹12.00
          per share

          For each share you hold, you will receive ₹12.00
          Dividend amount₹12.00 per share
          Dividend TypeFinal
          Ex Date25 Jul ‘25
          Record Date25 Jul ‘25
          Announcement date14 May ‘25

          14
          May
          Dividend
          Announced
          ₹12.00
          per share

          For each share you hold, you will receive ₹12.00
          Dividend amount₹12.00 per share
          Dividend TypeFinal
          Ex Date25 Jul ‘25
          Record Date25 Jul ‘25
          Announcement date14 May ‘25
          2024

          16
          Jul
          Dividend
          Ex date
          ₹8.00
          per share

          For each share you hold, you will receive ₹8.00
          Dividend amount₹8.00 per share
          Dividend TypeFinal
          Ex Date16 Jul ‘24
          Record Date16 Jul ‘24
          Announcement date6 May ‘24
          Events calendar
          View upcoming events in other stocks